{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-21-139500","form_type":"8-K","ticker":"PTPI","cik":"0001815903","company_name":"Petros Pharmaceuticals, Inc.","filed_at":"2021-11-16T23:59:59+00:00","discovered_at":"2026-05-14T18:04:14.283380+00:00","generated_at":"2026-06-28T07:52:33.510095+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Petros Pharma Q3 net sales fall 37% to $2.2M; net loss narrows to $1.7M","bullets":["Net sales $2.2M, down from $3.5M YoY; Prescription Medicines net sales declined 47% due to higher allowances and returns.","Net loss improved to $1.7M vs $3.3M YoY; adjusted EBITDA loss $1.9M.","Record STENDRA prescriptions and tablet sales; total mg sold up 6% sequentially.","Completed enrollment of pivotal label comprehension study for OTC switch of STENDRA; no FDA-approved OTC ED drug exists.","Cash $8.1M at Sep 30; raised $5.3M net in October 2021."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-21-139500","json":"https://secwatch.observer/filing/0001104659-21-139500.json","markdown":"https://secwatch.observer/filing/0001104659-21-139500.md","text":"https://secwatch.observer/filing/0001104659-21-139500.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1815903/000110465921139500/0001104659-21-139500-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1815903/000110465921139500/tm2133040d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-28T07:52:33.510095+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}